EP4153161 - THE COMBINATION OF ACETYL LEUCINE AND 4-AMINOPYRIDINE OR ACETAZOLAMIDE FOR TREATING ATAXIA [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 24.02.2023 Database last updated on 03.09.2024 | |
Former | The international publication has been made Status updated on 26.11.2021 | ||
Former | unknown Status updated on 09.06.2021 | Most recent event Tooltip | 13.03.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states IntraBio Ltd Summit House 170 Finchley Road London NW3 6BP / GB | [2023/13] | Inventor(s) | 01 /
STRUPP, Michael 81377 Munich / DE | [2023/13] | Representative(s) | Maiwald GmbH Elisenhof Elisenstraße 3 80335 München / DE | [2023/13] | Application number, filing date | 21728642.6 | 20.05.2021 | [2023/13] | WO2021IB54399 | Priority number, date | US202063028760P | 22.05.2020 Original published format: US 202063028760 P | [2023/13] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021234642 | Date: | 25.11.2021 | Language: | EN | [2021/47] | Type: | A1 Application with search report | No.: | EP4153161 | Date: | 29.03.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.11.2021 takes the place of the publication of the European patent application. | [2023/13] | Search report(s) | International search report - published on: | EP | 25.11.2021 | Classification | IPC: | A61K31/198, A61K31/433, A61K31/4409, A61P21/00, A61P25/00 | [2023/13] | CPC: |
A61P21/00 (EP,KR);
A61K31/198 (EP,KR,US);
A61K31/433 (EP,KR,US);
A61K31/4409 (EP,KR,US);
A61P25/00 (EP,KR);
A61P25/14 (US);
A61K2300/00 (KR)
(-)
| C-Set: |
A61K31/198, A61K2300/00 (EP);
A61K31/433, A61K2300/00 (EP);
A61K31/4409, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/13] | Title | German: | KOMBINATION VON ACETYLLEUCIN UND 4-AMINOPYRIDIN ODER ACETAZOLAMID ZUR BEHANDLUNG VON ATAXIE | [2023/13] | English: | THE COMBINATION OF ACETYL LEUCINE AND 4-AMINOPYRIDINE OR ACETAZOLAMIDE FOR TREATING ATAXIA | [2023/13] | French: | ASSOCIATION D'ACÉTYLLEUCINE ET DE 4-AMINOPYRIDINE OU D'ACÉTAZOLAMIDE POUR TRAITER L'ATAXIE | [2023/13] | Entry into regional phase | 13.12.2022 | National basic fee paid | 13.12.2022 | Designation fee(s) paid | 13.12.2022 | Examination fee paid | Examination procedure | 13.12.2022 | Examination requested [2023/13] | 13.12.2022 | Date on which the examining division has become responsible | 17.07.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 13.12.2022 | Renewal fee patent year 03 | 13.03.2024 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y] - ROMAN SCHNIEPP ET AL, "Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series", CEREBELLUM & ATAXIAS, (20160412), vol. 3, doi:10.1186/s40673-016-0046-2, page 8, XP055390569 [Y] 1-26 * page 1, column r, paragraph 1 - page 2, column r, paragraph 1 * * tables 1,2 * DOI: http://dx.doi.org/10.1186/s40673-016-0046-2 | [Y] - FEIL KATHARINA ET AL, "Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus", CEREBELLUM, TAYLOR AND FRANCIS, GB, vol. 15, no. 1, doi:10.1007/S12311-015-0733-1, ISSN 1473-4222, (20151030), pages 38 - 42, (20151030), XP035783963 [Y] 1-26 * page 39, column l, paragraph l - column r, paragraph 1 * * page 40, column l, paragraphs 2-3 * * page 40, column r, paragraph 2 - page 41, column l, paragraph 1 * * table 1 * DOI: http://dx.doi.org/10.1007/s12311-015-0733-1 | [XP] - PENKAVA JOSEF ET AL, "A novel pathogenicvariant causing episodic ataxia type 2 (EA2) spectrum phenotype in four family members and a novel combined therapy", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, (20201231), vol. 267, no. Suppl 1, doi:10.1007/S00415-020-10190-1, ISSN 0340-5354, pages 181 - 184, XP037311255 [XP] 1,2,4,5,7,11-19,21,23-26 * page S183, column l, paragraph 3 - column r, paragraph 1 * * page S182, column l, paragraph 2 * DOI: http://dx.doi.org/10.1007/s00415-020-10190-1 | by applicant | US9283181 | - ASHIZAWAXIA, Continuum (Minneap Min, (20160000), vol. 22, pages 1208 - 1226 | - KIPFERSTRUPP, Movement Disorders Clinical Practice, (20140000), vol. 1, pages 285 - 290 | - "Episodic ataxias", JEN JCWAN J, Handbook of clinical neurology, (20180000), vol. 155, pages 205 - 215 | - IMBRICI PEUNSON LHGRAVES TDBHATIA KPWADIA NHKULLMANN DMHANNA MG, "Late-onset episodic ataxia type 2 due to an in-frame insertion in CACNA1A", Neurology, (20050000), vol. 65, no. 6, pages 944 - 946 | - JEN JKIM GWBALOH RW, "Clinical spectrum of episodic ataxia type 2", Neurology, (20040000), vol. 62, no. 1, pages 17 - 22 | - RIANT et al., Revue Neurologique, (20110000), vol. 7, no. 57, pages 401 - 407 | - OPHOFF RATERWINDT GMVERGOUWE MNVAN EIJK ROEFNER PJHOFFMAN SMLAMERDIN JEMOHRENWEISER HWBULMAN DEFERRARI M, "Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4", Cell, (19960000), vol. 87, no. 3, doi:10.1016/S0092-8674(00)81373-2, pages 543 - 552, XP000647699 DOI: http://dx.doi.org/10.1016/S0092-8674(00)81373-2 | - ILG WBASTIAN AJBOESCH SBURCIU RGCELNIK PCLAASSEN JFEIL KKALLA RMIYAI INACHBAUER W, "Consensus paper: management of degenerative cerebellar disorders", Cerebellum (London, England, (20140000), vol. 13, no. 2, doi:10.1007/s12311-013-0531-6, pages 248 - 268, XP055588470 DOI: http://dx.doi.org/10.1007/s12311-013-0531-6 | - GANDINI et al., J Neurol., (20200000), vol. 267, pages 1211 - 1220 | - PATEL et al., "Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain", CNS Drugs, (20170000), vol. 31, pages 109 - 133 | - KABANOV et al., "New Technologies for Drug Delivery across the Blood Brain Barrier", Curr Pharm Des., (20040000), vol. 10, no. 12, pages 1355 - 1363 | - CHENG et al., "Highly Stabilized Curcumin Nanoparticles Tested in an In Vitro Blood-Brain Barrier Model and in Alzheimer's Disease Tg2576 Mice", The AAPS Journal, (20130000), vol. 15, no. 2, doi:10.1208/s12248-012-9444-4, pages 324 - 336, XP055624412 DOI: http://dx.doi.org/10.1208/s12248-012-9444-4 | - LAHDE et al., "Production of L-Leucine Nanoparticles under Various Conditions Using an Aerosol Flow Reactor Method", Journal of Nanomaterials, (20080000), vol. 2008 | - HANSON et al., "Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease", BMC Neurosci., (20080000), vol. 9, no. 3, doi:10.1186/1471-2202-9-S3-S5, page S5, XP021042511 DOI: http://dx.doi.org/10.1186/1471-2202-9-S3-S5 | - SINTAS et al., Sci Rep, (20170000), vol. 7, page 2514 | - KIM et al., J Clin Neurol, (20060000), vol. 2, pages 268 - 271 | - DENIER et al., Neurology, (19990000), vol. 52, pages 1816 - 1821 | - CHOICHOI, JMov Disord, (20160000), vol. 9, pages 129 - 135 | - ANGELINI et al., European Journal of Medical Genetics, (20190000), vol. 62, page 103530 | - GRIGGS RCMOXLEY RT, 3RDLAFRANCE RAMCQUILLEN J, "Hereditary paroxysmal ataxia: response to acetazolamide", Neurology, (19780000), vol. 28, no. 12, pages 1259 - 1264 | - KIPFER SSTRUPP M, "The Clinical Spectrum of Autosomal-Dominant Episodic Ataxias", Movement disorders clinical practice, (20140000), vol. 1, no. 4, pages 285 - 290 | - RIANT FVAHEDI KTOURNIER-LASSERVE E, "Hereditary episodic ataxia", Revue neurologique, (20110000), vol. 167, no. 5, pages 401 - 407 | - JEN JCGRAVES TDHESS EJHANNA MGGRIGGS RCBALOH RW, "Primary episodic ataxias: diagnosis, pathogenesis and treatment", Brain, (20070000), vol. 130, pages 2484 - 2493 | - ISAACS DABRADSHAW MJBROWN KHEDERA P, "Case report of novel CACNA1A gene mutation causing episodic ataxia type 2", SAGE open medical case reports, (20170000), vol. 5, page 2050313x17706044 | - GUTERMAN ELYURGIONAS BNELSON AB, "Pearls & Oy-sters: Episodic ataxia type 2: Case report and review of the literature", Neurology, (20160000), vol. 86, no. 23, pages e239 - 241 | - RICHARDS SAZIZ NBALE SBICK DDAS SGASTIER-FOSTER JGRODY WWHEGDE MLYON ESPECTOR E, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, (20150000), vol. 17, no. 5, pages 405 - 424 | - MANTUANO EROMANO SVENEZIANO LGELLERA CCASTELLOTTI BCAIMI STESTA DESTIENNE MZORZI GBUGIANI M, "Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2", Journal of the neurological sciences, (20100000), vol. 291, no. 1-2, doi:10.1016/j.jns.2010.01.010, pages 30 - 36, XP026934077 DOI: http://dx.doi.org/10.1016/j.jns.2010.01.010 | - MAKSEMOUS NROY BSMITH RAGRIFFITHS LR, "Next-generation sequencing identifies novel CACNA1A gene mutations in episodic ataxia type 2", Molecular genetics & genomic medicine, (20160000), vol. 4, no. 2, pages 211 - 222 | - ANGELINI CVAN GILS JBIGOURDAN AJOUK PSLACOMBE DMENEGON PMOUTTON SRIANT FSOLE GTOURNIER-LASSERVE E, "Major intra-familial phenotypic heterogeneity and incomplete penetrance due to a CACNA1A pathogenic variant", European journal of medical genetics, (20190000), vol. 62, no. 6, page 103530 | - STRUPP MKALLA RDICHGANS MFREILINGER TGLASAUER SBRANDT T, "Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine", Neurology, (20040000), vol. 62, no. 9, pages 1623 - 1625 | - STRUPP MKALLA RCLAASSEN JADRION CMANSMANN UKLOPSTOCK TFREILINGER TNEUGEBAUER HSPIEGEL RDICHGANS M, "A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias", Neurology, (20110000), vol. 77, no. 3, pages 269 - 275 | - KALLA RSTRUPP M, "Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders", Current neuropharmacology, (20190000), vol. 17, no. 1, pages 7 - 13 |